Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
08 Feb 2024
08 Feb 2024
Historique:
received:
12
11
2023
accepted:
24
01
2024
revised:
18
01
2024
medline:
9
2
2024
pubmed:
9
2
2024
entrez:
8
2
2024
Statut:
aheadofprint
Résumé
Peripheral T-cell lymphomas (PTCL) other than anaplastic large-cell lymphoma are rare in children, and the role of hematopoietic stem cell transplantation (HSCT) has not been clarified yet. In a retrospective analysis of registry-data of the European Society for Blood and Marrow Transplantation we analyzed 55 patients aged < 18 years who received allogeneic (N = 46) or autologous (N = 9) HSCT for PTCL. Median age at HSCT was 13.9 years; 33 patients (60%) were in first remission, and 6 (19%) in progression at HSCT. Conditioning was myeloablative in 87% of the allogeneic HSCTs and in 27 (58.7%) based on total body irradiation. After allogeneic HSCT the 5-year overall- and progression-free survival was 58.9% (95% CI 42.7-71.9) and 52.6% (95% CI 36.8-66.1), respectively. 5-year relapse incidence was 27.6% (95% CI 15.1-41.6), the non-relapse mortality rate was 19.8% (95% CI 9.7-32.6). Five of the six patients with progression at HSCT died. Seven of nine patients after autologous HSCT were alive and disease-free at last follow-up. Our data suggest a role of allogeneic HSCT in consolidation-treatment of patients with high-risk disease, who reach at least partial remission after primary- or relapse-therapy, whereas patients with therapy-refractory or progressive disease prior to transplantation do not profit from HSCT.
Identifiants
pubmed: 38331982
doi: 10.1038/s41409-024-02226-1
pii: 10.1038/s41409-024-02226-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon. (2017).
Kobayashi R, Yamato K, Tanaka F, Takashima Y, Inada H, Kikuchi A, et al. Retrospective analysis of nonanaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer. 2010;54:212–5.
doi: 10.1002/pbc.22329
pubmed: 19856396
Kontny U, Oschlies I, Woessmann W, Burkhardt B, Lisfeld J, Salzburg J, et al. Non-anaplastic peripheral T-cell lymphoma in children and adolescents—a retrospective analysis of the NHL-BFM study group. Br J Haematol. 2015;168:835–44.
doi: 10.1111/bjh.13216
pubmed: 25395120
Windsor R, Stilles C, Webb D. Peripheral T-cell lymphomas in childhood: population-based experience in the United Kingdom over 20 years. Pediatr Blood Cancer. 2008;50:784–7.
doi: 10.1002/pbc.21293
pubmed: 18022899
Flower A, Xavier AC, Cairo MS. Mature (non-anaplastic, non-cutaneous) T-/NK-cell lymphomas in children, adolescents and young adults: state of the science. Br J Haematol. 2019;185:418–35.
doi: 10.1111/bjh.15767
pubmed: 30706450
Au-Yeung RK, Richter J, Abramov ID, Bacon CM, Balagué O, d’Amore ES, et al. Molecular features of non-anaplastic peripheral T-cell lymphoma in children and adolescents. Pediatr Blood Cancer. 2021. https://doi.org/10.1002/pbc.29285 .
Mellgren K, Attarbaschi A, Abla O, Alexander S, Bomken S, Bubanska E, et al. Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases. Ann Hematol. 2016;95:1295–305.
doi: 10.1007/s00277-016-2722-y
pubmed: 27270301
Al Mahmoud R, Weitzman S, Schechter T, Ngan B, Abdelhaleem M, Alexander S, et al. Peripheral T-cell lymphoma in children and adolescents: a single-institution experience. J Pediatr Hematol Oncol. 2012;34:611–6.
doi: 10.1097/MPH.0b013e3182707592
pubmed: 23042011
Hutchison RE, Laver JH, Chang M, Muzzafar T, Desai S, Murphy S, et al. Non-anaplastic peripheral Tcell lymphoma in childhood and adolescence: a Children’s Oncology Group study. Pediatr Blood Cancer. 2008;51:29–33.
doi: 10.1002/pbc.21543
pubmed: 18300314
pmcid: 4447625
Sandlund JT, Perkins SL. Uncommon non-Hodgkin lymphomas of childhood: pathological diagnosis, clinical features and treatment approaches. Br J Haematol. 2015;169:631–46.
doi: 10.1111/bjh.13359
pubmed: 25851546
Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24:265–84.
doi: 10.1038/leu.2009.257
pubmed: 20010625
Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S, et al. Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage-a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 1995;13:359–72.
doi: 10.1200/JCO.1995.13.2.359
pubmed: 7844597
Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000;95:416–21.
pubmed: 10627444
Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 1999;94:3294–306.
pubmed: 10552938
Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;28:3987–93.
doi: 10.1200/JCO.2010.28.5999
pubmed: 20679620
Wrobel G, Mauguen A, Rosolen A, Reiter A, Williams D, Horibe K, et al. Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer. 2011;56:1071–7.
doi: 10.1002/pbc.22940
pubmed: 21280197
Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.
doi: 10.1200/JCO.2008.16.4558
pubmed: 18626005
Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29:715–23.
doi: 10.1093/annonc/mdx787
pubmed: 29253087
Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J, et al. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol. 2016;91:672–6.
doi: 10.1002/ajh.24372
pubmed: 27012928
Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570–7.
doi: 10.1182/blood-2014-04-573089
pubmed: 25006130
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25:2211–7.
doi: 10.1093/annonc/mdu443
pubmed: 25193992
pmcid: 4481543
Mehta N, Maragulia JC, Moskowitz A, Hamlin PA, Lunning MA, Moskowitz CH, et al. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk. 2013;13:664–70.
doi: 10.1016/j.clml.2013.07.005
pubmed: 24035712
Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J. 2016;6:e452 https://doi.org/10.1038/bcj.2016.63 .
doi: 10.1038/bcj.2016.63
pubmed: 27471868
pmcid: 5030384
d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9.
doi: 10.1200/JCO.2011.40.2719
pubmed: 22851556
Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated upfront with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20:1533–8.
doi: 10.1038/sj.leu.2404306
pubmed: 16871285
Kobayashi R, Fujita N, Mitsui T, Iwasaki F, Suzumiya J, Kuroda H, et al. Stem cell transplantation for paediatric patients with non-anaplastic peripheral T-cell lymphoma in Japan. Br J Haematol. 2012;159:88–93.
doi: 10.1111/bjh.12001
pubmed: 22881201
Attarbaschi A, Abla O, Padilla LA, Beishuizen A, Burke GA, Brugières L, et al. Rare non-Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma. Pediatr Blood Cancer. 2020;67:e28416 https://doi.org/10.1002/pbc.28416 .
doi: 10.1002/pbc.28416
pubmed: 32452165
Mollee P, Lazarus HM, Lipton J. Why aren’t we performing more allografts for aggressive non-Hodgkin’s lymphoma? Bone Marrow Transpl. 2003;31:953–60.
doi: 10.1038/sj.bmt.1704040
Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, et al. Graft-versus lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol. 2008;26:2264–71.
doi: 10.1200/JCO.2007.14.1366
pubmed: 18390969
Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood 2021;137:2646–56.
pubmed: 33512419
pmcid: 9635528
Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22:2172–6.
doi: 10.1200/JCO.2004.12.050
pubmed: 15169805
Castagna L, Pagliardini T, Bramanti S, Schiano de Colella JM, Montes de Oca C, Bouabdallah R, et al. Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. Bone Marrow Transpl. 2021;56:883–9.
doi: 10.1038/s41409-020-01133-5
Zhang JY, Briski R, Devata S, Kaminski MS, Phillips TJ, Mayer TL, et al. Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL). Am J Hematol. 2018;93:394–400.
doi: 10.1002/ajh.24992
pubmed: 29194714
Huang H, Jiang Y, Wang Q, Guo L, Jin Z, Fu Z, et al. Outcome of Allogeneic and Autologous Hematopoietic Cell Transplantation for High-Risk Peripheral T Cell Lymphomas: A Retrospective Analysis From a Chinese Center. Biol Blood Marrow Transpl. 2017;23:1393–7.
doi: 10.1016/j.bbmt.2017.04.021